Amid a spike in Covid-19 instances and a serious deficit of Remdesivir, Hyderabad-based pharma major Dr. Reddy’s Laboratories isn’t only ramping up production of this medication but has decided to slash the most retail cost by half in the interest of patients.
The organization said it will also be rolling out a liquid version of Redyx, its own Remdesivir brand, which is quicker to manufacture and distribute.
“We’re making every attempt to make sure the Dr. Reddy’s Remdesivir, marketed under the brand name Redyx, reaches as many individuals in India as you can. We’re ramping up manufacturing and therefore are also bringing to advertise a liquid product which is quicker to create and provide,” the firm said.
“We also have reduced our MRP by 50% in order that cost isn’t a barrier to access, and also a far larger number of individuals may get it,” it added.
To guarantee whole visibility on the access to the medication to patients and health professionals, the company has established a dedicated site that’s updated in real-time to reveal city-wise access to Redyx and Favipiravir at different stockists and hospitals throughout the nation.